{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:42:53Z","timestamp":1780537373368,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102165","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T10:22:26Z","timestamp":1721125346000},"page":"102165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Clinicopathological Characteristics and Prognosis of 55 Patients With TFE3-Rearranged Renal Cell Carcinomas"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8874-5212","authenticated-orcid":false,"given":"Yin-Miao","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0483-0899","authenticated-orcid":false,"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1658-953X","authenticated-orcid":false,"given":"Xiang-Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Di","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong-Yi","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3991-3750","authenticated-orcid":false,"given":"Hong-Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clgc.2024.102165_bib0001","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/cancers11081110","article-title":"MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge","volume":"11","author":"Cali\u00f2","year":"2019","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clgc.2024.102165_bib0002","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 world health organization classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102165_bib0003","first-page":"23","article-title":"WHO 2022 classification of kidney tumors: what is relevant? An update and future novelties for the pathologist","volume":"115","author":"Cali\u00f2","year":"2023","journal-title":"Pathologica"},{"issue":"9","key":"10.1016\/j.clgc.2024.102165_bib0004","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq029","article-title":"Targeted agents in metastatic Xp11 translocation\/TFE3 gene fusion renal cell carcinoma (RCC): a report from the juvenile RCC network","volume":"21","author":"Malouf","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102165_bib0005","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1002\/cncr.25512","article-title":"Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma","volume":"116","author":"Choueiri","year":"2010","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2024.102165_bib0006","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/oncolo\/oyac158","article-title":"Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas","volume":"27","author":"Thouvenin","year":"2022","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.clgc.2024.102165_bib0007","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102165_bib0008","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (espn): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102165_bib0009","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase ii study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102165_bib0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1634\/theoncologist.2019-0372","article-title":"Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single institutional experience and literature meta analysis","volume":"25","author":"Chahoud","year":"2020","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.clgc.2024.102165_bib0011","first-page":"881","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet North Am Ed"},{"issue":"21","key":"10.1016\/j.clgc.2024.102165_bib0012","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non\u2013clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.clgc.2024.102165_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110190","article-title":"Integrative clinical and molecular characterization of translocation renal cell carcinoma","volume":"38","author":"Bakouny","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.clgc.2024.102165_bib0014","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12894-018-0419-3","article-title":"Bilateral Xp11.2 translocation renal cell carcinoma: a case report","volume":"18","author":"Karashima","year":"2018","journal-title":"BMC Urol"},{"issue":"28","key":"10.1016\/j.clgc.2024.102165_bib0015","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.12998\/wjcc.v10.i28.10180","article-title":"Chemotherapy, transarterial chemoembolization, and nephrectomy combined treated one giant renal cell carcinoma (T3aN1M1) associated with Xp11.2\/TFE3: a case report","volume":"10","author":"Wang","year":"2022","journal-title":"World J Clin Cases"},{"issue":"19","key":"10.1016\/j.clgc.2024.102165_bib0016","doi-asserted-by":"crossref","first-page":"e873","DOI":"10.1097\/MD.0000000000000873","article-title":"Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.clgc.2024.102165_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166897","article-title":"Renal cell carcinoma associated with Xp11.2 translocation\/TFE3 gene fusions: clinical features, treatments and prognosis","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clgc.2024.102165_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110190","article-title":"Integrative clinical and molecular characterization of translocation renal cell carcinoma","volume":"38","author":"Bakouny","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.clgc.2024.102165_bib0019","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00330-016-4421-4","article-title":"Renal cell carcinoma associated with Xp11.2 translocation\/TFE gene fusion: imaging findings in 21 patients","volume":"27","author":"Chen","year":"2017","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102165_bib0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/jcrt.jcrt_1505_22","article-title":"Imaging findings, clinical and pathological characters of 28 patients with Xp11.2\/TFE3 translocation renal cell carcinoma","volume":"19","author":"Dong","year":"2023","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"10.1016\/j.clgc.2024.102165_bib0021","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10024-004-9106-3","article-title":"Pediatric renal carcinoma associated with Xp11.2 translocations\/TFE3 gene fusions and clinicopathologic associations","volume":"8","author":"Altinok","year":"2005","journal-title":"Pediatr Dev Pathol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102165_bib0022","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1309\/AJCPQ6LLFMC4OXGC","article-title":"Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis","volume":"137","author":"Klatte","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102165_bib0023","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.18632\/aging.205452","article-title":"Therapeutic strategies and predictive models for Xp11.2 translocation\/TFE3 gene fusion renal cell carcinoma in adults based on data of two Chinese medical centers","volume":"16","author":"Yang","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.clgc.2024.102165_bib0024","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1038\/s41598-023-33363-0","article-title":"Estrogen associates with female predominance in Xp11.2 translocation renal cell carcinoma","volume":"13","author":"Lu","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.clgc.2024.102165_bib0025","doi-asserted-by":"crossref","first-page":"e16076","DOI":"10.1016\/j.heliyon.2023.e16076","article-title":"TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma","volume":"9","author":"Lin","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.clgc.2024.102165_bib0026","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12894-022-01060-1","article-title":"Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation\/TFE3 gene fusion renal cell carcinomas","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Urol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102165_bib0027","first-page":"165","article-title":"Clinicopathologic features and prognosis of Xp11.2\/TFE3 gene fusion associated renal cell carcinoma in adults","volume":"43","author":"Wang","year":"2022","journal-title":"Chin J Urol"},{"key":"10.1016\/j.clgc.2024.102165_bib0028","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/s41598-020-59162-5","article-title":"Comparative clinicopathologic characteristics and outcomes of paediatric and adult Xp11 translocation renal cell carcinomas: a retrospective multicentre study in China","volume":"10","author":"Ma","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2024.102165_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2022.151908","article-title":"Renal cancer associated with Xp11.2 translocation\/TFE3 gene fusion: clinicopathological analysis of 13 cases","volume":"58","author":"Feng","year":"2022","journal-title":"Ann Diagn Pathol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:58:19Z","timestamp":1738565899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324001368"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102165","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Clinicopathological Characteristics and Prognosis of 55 Patients With TFE3-Rearranged Renal Cell Carcinomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102165"}}